Health reform has dominated the U.S. political agenda throughout 2009, with President Obama and Congressional leaders working to effect a substantial overhaul of the health care system. The stakes are high, both for U.S.-based and European-based biopharma companies.
Both the House and Senate are debating policies that would significantly expand the market for drugs and devices; but with an estimated 10-year price tag of $1 trillion dollars, the proposals also include significant cost-cutting measures that would have a deep impact on the drug and device industries.
As Congress returns to Washington from its August recess, and the legislation enters its most critical phase, join us on this Sept. 10 webinar to carefully analyze areas of potential risk for manufacturers and address important questions such as:
• How will key reimbursement issues--such as the Medicaid rebate percentage, changes to the definition of the Average Manufacturer Price (AMP), negotiation of Part D prices, or payment rates for imaging equipment and DME--be impacted by health reform?
• Will government cost-containment efforts impose new comparative effectiveness requirements upon manufacturers?
• How will the changes in FDA law impact innovators’ strategies to preserve market exclusivity?
• How will manufacturers be affected by new reporting and transparency requirements, such as the physician payments sunshine provisions or the national device registry?
• How will the measures to improve the quality of care, including hospital readmission penalties, accountable care organizations, and bundled payment for post-acute care impact manufacturers?
Get the inside scoop live from Washington on this exclusive webinar! Get your questions answered without ever leaving your office. Join us Sept. 10 at 6 pm CET/5 pm WET.
To register, visit:
